NCT05994001: Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Sponsor: Shanghai Zhongshan Hospital. Phase: PHASE1. Conditions: Biliary Tract Cancer, Candonilimab, Claudin 18.2